WX-037

The PI3K-Inhibitor project was acquired from UCB at the beginning of 2009. The phosphatidylinositol-3-kinase/proteine-kinase-(PI3K) signalling pathway sends a “growth” signal to the nucleus of a tumour cell. It has also been shown that abnormal mutations of the PI3K signalling pathway are present in most types of cancer. Identifying an inhibitor for the PI3K signalling pathway is thus of therapeutic interest.

Status

The drug candidate WX-037 was selected as the lead compound for the oral small-molecule PI3K inhibitor, and a development plan has been prepared.